Use of inhibitors of Bruton's tyrosine kinase (Btk)

  • US 8,999,999 B2
  • Filed: 01/22/2013
  • Issued: 04/07/2015
  • Est. Priority Date: 06/03/2010
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic leukemia in an individual comprising administering to the individual in need thereof once per day between about 280 mg to about 840 mg of an oral dose of an irreversible inhibitor of Bruton'"'"'s tyrosine kinase (Btk), having the structure:

View all claims

    Thank you for your feedback